Pioneer and Novo Nordisk crown Melio Bio winner of 2025 Golden Ticket Programme
Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer Group and Novo Nordisk’s 2025 Golden Ticket Programme.
The 2025 Golden Ticket Programme was open to early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare endocrine disorders, with robust research plans and potential for successful research development.